NYKODE THERAPEUTICS ASA: årsregnskap 2025 vs 2024
Shrank 95% on revenue, stronger earnings, fresh owner capital
approved 2026-05-13; registry 2026-08-10; journal 2026 705017
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for NYKODE THERAPEUTICS ASA. Revenue 9.16m NOK → 453.0k NOK (-95.1%). Net result -38.48m NOK → -12.67m NOK. Equity 140.14m NOK → 94.98m NOK.
On the constructive side: operating result improved; net result improved; owners injected capital. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: book investments changed. All figures are taken from the published annual accounts for NYKODE THERAPEUTICS ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -45.75m NOK → -29.16m NOK (op. margin -499.5% → -6437.5%). Calculated
-
↑
Net result improved
Net result -38.48m NOK → -12.67m NOK (net margin -420.2% → -2797.6%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 144.9k NOK → 112.61m NOK (+112.47m NOK). Reported fact
-
↑
Payroll decreased
Salary cost 19.74m NOK → 9.14m NOK (216% → 2018% of revenue). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 9.16m NOK to 453.0k NOK (-95.1% YoY). Calculated
-
↓
Equity eroded
Book equity 140.14m NOK → 94.98m NOK (equity ratio 89.8% → 92.5%). Calculated
-
↓
Cash fell
Bank deposits 114.02m NOK → 59.27m NOK (-48.0% YoY). Calculated
Things to notice
-
·
Book investments changed
Investment / intangible book value 4.77m NOK → 4.58m NOK. Reported fact